Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RDEA806 in Hyperuricemic Gout
NCT00741442Phase 2Completed
- Sponsor
- Ardea Biosciences, Inc.
- Start
- Jul 2008
- Primary completion
- Apr 2009
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of RDEA806 in gout and hyperuricemia (4 arms), sponsored by Ardea Biosciences, Inc. Primary endpoint: Proportion of subjects whose serum uric acid (sUA) level is <6.0 mg/dL at 4 weeks. Started Jul 2008; status: completed.
02
Drugs
RDEA806
03
Conditions
gouthyperuricemia
Beyond the preview
Go deeper on NCT00741442.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00741442.